Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 9, 2026
Perspective Therapeutics reports 3Q 2026 results, with approximately $202 million in cash, cash equivalents, and short-term investments as of September 30, 2026.
NYSE American: $CATXRadiopharmaceuticalsTargeted alpha therapyThree clinical programmesNo approval · equity below cash
CATX Stock Hub: Perspective Therapeutics News, Alpha Therapy and Neuroendocrine Tumors
Perspective Therapeutics held approximately $202 million of cash, cash equivalents and short-term investments at September 30, 2026, says that is sufficient to fund its current planned clinical milestones and operational investments into 2028, and has no approved product. The shares closed at $0.84 on November 6, 2026, valuing the company at about $101.4 million, below the cash on the last balance sheet. The next major checkpoint is an End-of-Phase 2 meeting with the FDA in the first quarter of 2027, the gate to a Phase 3 study in neuroendocrine tumors. Third-quarter release, November 9, 2026
Full research report · PDF
Perspective Therapeutics ($CATX) research report, as of November 9, 2026
22 pages: the lead-212 platform and chelator, the VMT-α-NET data across ESMO, NANETS and ASCO, VMT01 in melanoma, PSV359 and the Merck collaboration, the Fast Track and European orphan designations, the Phase 3 design and the End-of-Phase 2 question, six quarters of results, cash and the runway calculation, the February offering and the at-the-market facility, ownership including Lantheus, management, catalysts and FAQ. Available in the Merlintrader Research Library. The report is a dated snapshot and is not updated after that date; this page follows the current situation.
Next catalyst
First quarter of 2027 · End-of-Phase 2 meeting with the FDA for VMT-α-NET
The company said on November 5, 2026 that it targets the meeting in the first quarter of 2027, that it is folding the SSTR2-enrichment analysis into the regulatory discussion on the registration-enabling study, and that FDA feedback and the remaining work are expected to allow the Phase 3 to start in 2027. The date is company guidance at quarter level; no day has been announced. NANETS release, November 5, 2026
The company reaffirmed the first-quarter 2027 target in its third-quarter release of November 9, 2026, adding that pre-Phase 3 activities are progressing and that the dose-finding Cohort 4 for neuroendocrine tumors closed for recruitment with 20 patients enrolled as of October 30, 2026. Third-quarter release. Before that: Phase 3 site start-up preparations, which the company aimed to complete around year-end 2026. VMT-α-NET data are due at the EORTC-NCI-AACR Symposium on November 20, 2026.
CATX stock at a glance
Close · Nov 6, 2026
$0.84
Regular-session NYSE American close; the shares traded between $0.7814 and $6.16 over the past twelve months.
Market value
~$101.4M
120,758,815 shares at $0.84; share count at November 4, 2026 from the Form 10-Q cover, a calculation.
Cash and investments · Sep 30, 2026
~$202M
Company-reported approximate figure for cash, cash equivalents and short-term investments, against about $145M at December 31, 2025 ($236.9M at June 30, 2026).
Net loss · Q3 2026
−$32.4M
Against $26.0M in the same quarter of 2025; $0.27 per share.
R&D · Q3 2026
$26.1M
Up from $20.3M a year earlier; general and administrative costs $8.3M versus $7.7M.
Operating cash burn · Q3 2026
$31.4M
Derived from $83.470M used in the first nine months and $52.118M in the first half.
Shares and overhang
120.76M
Shares at November 4, 2026, after the 2026 pre-funded warrants were exercised in full in October; a further 13,672,484 options and 338,715 warrants at September 30, 2026.
At-the-market capacity
$239.8M
Available under the $250 million sales agreement at March 12, 2026.
Where Perspective Therapeutics stands now
Third-quarter results, November 9, 2026. Perspective reported cash, cash equivalents and short-term investments of approximately $202 million at September 30, 2026 (about $145 million at December 31, 2025), which it believes is sufficient to fund current planned clinical milestones and operational investments into 2028. The net loss for the quarter was $32.4 million ($0.27 per share), with research and development expenses of $26.1 million and general and administrative expenses of $8.3 million. The company reports that the dose-finding Cohort 4 for neuroendocrine tumors closed for recruitment with 20 patients enrolled as of October 30, that the meningioma cohort remains open with two patients treated, that 12 patients had been treated in the VMT01 monotherapy cohort (five since it reopened in the third quarter, with the cohort still open), that 17 patients had been treated across the three PSV359 cohorts at September 30 with the next clinical update planned for 2027, and that construction at the Chicago-area site is expected to be completed in early 2027. Third-quarter release · Form 10-Q, September 30, 2026
Perspective attaches the alpha emitter lead-212 to peptides that bind receptors over-expressed on tumors, and pairs each therapeutic with a lead-203 imaging version so the target can be seen before treatment. Three programmes are in Phase 1/2a studies in the United States: VMT-α-NET in somatostatin receptor type 2 neuroendocrine tumors, VMT01 in MC1R-positive melanoma and PSV359 in FAP-expressing solid tumors; a fourth, PSV594, is preclinical. The company has no approved product, no product revenue and a grant line that produced $0.157 million in the first half of 2026. Form 10-Q, June 30, 2026
The main risk: the Phase 3 has not started, and the share price decides what it costs to fund. At $0.84 the company is worth $101.4 million against approximately $202 million of cash and investments at September 30, 2026. It can fund the current plan into 2028 on its own guidance, but a registration study in a rare tumor would need either a partner or an equity raise at a price that issues shares far faster than the February offering did: the $239.8 million still available under the at-the-market facility at March 12, 2026 equals about 285 million shares at today's price, against 120.8 million outstanding at November 4.
▲ The constructive case
In 57 GEP-NET patients whose target lesions all express SSTR2, the objective response rate was 39% (22 of 57), disease control 95% (54 of 57) and progression-free survival 75% at 18 months, against a 13% response rate and roughly 65% progression-free survival at 18 months in the U.S. label of the approved beta-emitting comparator, as the company frames it. European orphan designation for GEP-NETs arrived on July 28, 2026, FDA Fast Track for PSV359 on October 8, and a Merck collaboration on September 14. With approximately $202 million at September 30, the company says the plan is funded into 2028.
▼ The cautious case
The data are single-arm, open-label and small by cohort, and the SSTR2-enriched analysis is retrospective, as the company labels it. Grade 3 events occurred in 29% of 68 patients at ESMO, including two grade 3 renal events, and renal function is being followed over longer exposure. The February offering sold 39.6 million shares and pre-funded warrants for 6.6 million more at $3.79, so the next raise would be more dilutive. Lantheus has been selling.
Latest CATX news
Nov 9, 2026
Perspective Therapeutics Provides Recent Business Highlights and Reports 3Q 2026 Results
Perspective Therapeutics reported approximately $202 million in cash, cash equivalents, and short-term investments as of September 30, 2026, expected to fund planned clinical milestones into 2028. Research and development expenses were $26.1 million for the three months ended September 30, 2026, compared to $20.3 million a year earlier. Net loss was $32.4 million, or $0.27 per basic and diluted share, compared to $26.0 million, or $0.35 per share, in 3Q 2025. PSV359 received FDA Fast Track Designation for FAP-positive solitary fibrous tumors.
Nov 6, 2026
Perspective Therapeutics presents promising 212Pb-lapemelanotide zapixetar (VMT01) monotherapy data
Perspective Therapeutics presented updated interim monotherapy results from its Phase 1/2a trial of [212Pb]lapemelanotide zapixetar (VMT01) at SITC 2026 in Phoenix, Arizona. At the 3.0 mCi dose, two of eight monotherapy patients had objective partial responses, and the disease control rate was 75%. No dose-limiting toxicities or treatment-related serious treatment-emergent adverse events were reported across 20 patients in three monotherapy cohorts.
Nov 5, 2026
Perspective Presents Incremental Data on 212Pb Bamzireotide Navoxetan in SSTR2 NETs
At the NANETS 2026 symposium, Perspective presented incremental analyses of its Phase 1/2a trial of [212Pb]VMT-α-NET (bamzireotide navoxetan) in SSTR2-expressing NETs. In 57 GEP-NET patients whose target lesions all express SSTR2, progression free survival was 75% at 18 months, disease control was seen in 92% of Cohort 2 and 100% of Cohort 3 patients, and responses were seen in 37% and 47% of those cohorts. Bamzireotide remained well-tolerated, with no dose-limiting toxicities. The company is targeting an end-of-Phase 2 meeting in the first quarter of 2027.
CATX stock catalysts: the dated calendar
- November 20, 2026 — VMT-α-NET data at the EORTC-NCI-AACR Symposium. Announced
- November 9, 2026 — Third-quarter 2026 results and business update: cash of about $202 million at September 30, End-of-Phase 2 target of the first quarter of 2027 reaffirmed. Completed
- Around year-end 2026 — Completion of Phase 3 site start-up preparations for VMT-α-NET. Company target
- First quarter of 2027 — End-of-Phase 2 meeting with the FDA for VMT-α-NET. Company guidance
- Early 2027 — Construction completion at the Chicago-area manufacturing site. Company guidance
- 2027 — Phase 3 initiation in neuroendocrine tumors, and the next PSV359 clinical update. Company guidance
- Second half of 2027 — Los Angeles-area site completed; four regional manufacturing sites by year-end. Company guidance
- Mid-2027 — The five VMT01 monotherapy patients treated since the cohort reopened in the third quarter are expected to reach at least 24 weeks of follow-up. Company expectation
- Into 2028 — Period the company says its September 30 cash can fund current planned clinical milestones and operational investments. Company guidance
The three clinical programmes and what each has shown
| Programme | Target and setting | Latest data | Next step |
|---|---|---|---|
| VMT-α-NET bamzireotide navoxetan | SSTR2-positive neuroendocrine tumors, no prior radiopharmaceutical therapy; 68 patients in Cohorts 1-3 at ESMO, 76 treated across four cohorts at July 31, 2026; Cohort 4 closed for recruitment with 20 patients enrolled as of October 30, 2026 | ORR 33% in Cohort 2 and 50% in Cohort 3; DCR 89% and 95%; PFS 72% at 18 months; in the SSTR2-enriched GEP-NET group ORR 39% and PFS 75% at 18 months | End-of-Phase 2 meeting, first quarter of 2027 |
| VMT01 lapemelanotide zapixetar | MC1R-positive metastatic melanoma, second line or later; 27 patients enrolled at July 31, 2026, monotherapy and with nivolumab; 12 patients treated in the monotherapy cohort as of October 30, 2026 | At 3.0 mCi monotherapy, 2 partial responses in 8 patients, DCR 75%; no DLTs across 20 monotherapy patients; grade 3 or higher events 25%, none related | Combination data after 24 weeks of follow-up; no date |
| PSV359 | FAP-expressing solid tumors; 17 patients treated across three cohorts at September 30, 2026 | Dose-finding; first three monotherapy cohorts completed enrollment; early imaging supports tumor uptake and renal clearance | Next clinical update planned for 2027; Merck combination amendment |
Sources: third-quarter release, November 9, 2026; ESMO release, October 23, 2026; NANETS release, November 5, 2026; SITC release, November 6, 2026; second-quarter release, August 10, 2026.
Merlintrader Health Score · $CATX
3.2out of 5
Assessed on November 9, 2026, after the clinical data releases of November 5 and 6, 2026, and re-assessed the same day after the third-quarter results, with the scores unchanged (lower cash, a wider quarterly loss and more shares outstanding are offset by the longer stated runway and the reaffirmed regulatory timetable). Calculation: 0.30 × 4.0 + 0.30 × 3.5 + 0.20 × 2.0 + 0.10 × 2.0 + 0.10 × 3.5 = 1.20 + 1.05 + 0.40 + 0.20 + 0.35 = 3.20, rounded to 3.2. The score describes financial and operational robustness over twelve to eighteen months. It is not a rating, a target price or an indication to buy or sell.
Red flags
- The equity is worth about $101.4 million against approximately $202 million of cash and investments at September 30, 2026: the market is valuing the pipeline, the Phase 3 cost and the next financing at less than zero.
- No approved product, no product revenue and no partner funding development; grant revenue fell to $0.157 million in the first half of 2026.
- The Phase 3 has not started and depends on an FDA meeting guided only to the first quarter of 2027.
- Cash fell from $236.9 million at June 30 to approximately $202 million at September 30, 2026, and the quarterly net loss widened to $32.4 million from $26.0 million a year earlier.
- The share count rose 54% in one transaction in February 2026, and $239.8 million of at-the-market capacity remained at March 12, 2026.
- 13,672,484 options and 338,715 warrants were outstanding at September 30, 2026; the 6,598,046 pre-funded warrants were exercised in full in October 2026.
- Approximately $54.5 million of contracted construction and a $9.9 million thorium take-or-pay commitment land before any revenue.
- Grade 3 events in 29% of patients at ESMO, including two grade 3 renal events, with renal function still being characterised.
- Lantheus, which holds an option on VMT-α-NET, cut its stake from 11,677,339 shares to 8,739,011 between April and September 2026.
CATX Stock FAQ: Perspective Therapeutics Questions Answered
When is the next CATX catalyst?
The End-of-Phase 2 meeting with the FDA for VMT-α-NET, which the company guided to the first quarter of 2027 on November 5 and reaffirmed in its third-quarter release of November 9, 2026, with Phase 3 initiation expected in 2027. Site start-up preparations were targeted around year-end 2026, and VMT-α-NET data are due at the EORTC-NCI-AACR Symposium on November 20, 2026. Third-quarter release · NANETS release · ESMO release
Is Perspective Therapeutics’ VMT-α-NET FDA approved?
No. As of November 10, 2026, [212Pb]VMT-α-NET is investigational and has no marketing approval in the United States or the European Union. Since July 28, 2026, it has held European orphan medicinal product designation for the treatment of gastroenteropancreatic neuroendocrine tumors, while it is evaluated in an ongoing Phase 1/2a study. European designation
How much cash does Perspective Therapeutics have, and how long will it last?
Approximately $202 million of cash, cash equivalents and short-term investments at September 30, 2026, against approximately $145 million at December 31, 2025 and $236.9 million at June 30, 2026. The company says that amount is sufficient to fund its current planned clinical milestones and operational investments into 2028. Third-quarter release · Form 10-Q · second-quarter Form 10-Q
Is CATX stock at risk of dilution?
Yes. At September 30, 2026, Perspective had 13,672,484 options and 338,715 warrants outstanding, and the holder of the 2026 pre-funded warrants for 6,598,046 shares exercised all of them in October 2026. The February 2026 registered offering issued 39,576,088 shares, and the company has a 2024 at-the-market sales agreement for up to $250 million of common stock. Form 10-Q
When does Perspective Therapeutics report earnings?
Perspective reported third-quarter 2026 results, for the quarter ended September 30, 2026, on November 9, 2026, together with a business update. As of November 10, 2026, the company has not announced the date of its fourth-quarter and full-year 2026 results. Third-quarter release
What does Perspective Therapeutics do?
Perspective Therapeutics is a clinical-stage radiopharmaceutical company in Seattle that attaches the alpha emitter lead-212 to peptides targeting tumor receptors. Its programmes are VMT-α-NET in neuroendocrine tumors, VMT01 in melanoma and PSV359 in FAP-positive solid tumors, with a preclinical fourth, PSV594.
What did Perspective Therapeutics’ ESMO data show for VMT-α-NET?
In data released at ESMO on October 23, 2026, covering 68 patients across three cohorts, the objective response rate was 33% in Cohort 2 and 50% in Cohort 3, disease control 89% and 95%, and progression-free survival 72% at 18 months. Grade 3 events occurred in 29% of patients, with two grade 3 renal events. ESMO release
Is Lantheus selling its CATX shares?
Yes. In a Schedule 13D/A filed on September 23, 2026, Lantheus reported 8,739,011 shares, or 7.7% of the common stock, as of September 22, 2026. It reported open-market sales on seven days between September 4 and September 22, 2026, at average prices from $2.85 to $3.1472 a share. Schedule 13D/A
Primary sources
- Third-quarter 2026 results and business highlights, November 9, 2026
- Form 10-Q, quarter ended September 30, 2026
- Form 10-Q, quarter ended June 30, 2026
- Form 10-K, year ended December 31, 2025
- VMT-α-NET analyses at NANETS, November 5, 2026
- VMT01 melanoma data at SITC, November 6, 2026
- VMT-α-NET interim results at ESMO, October 23, 2026
- FDA Fast Track designation for PSV359, October 8, 2026
- Clinical collaboration with Merck, September 14, 2026
- Second-quarter 2026 results, August 10, 2026
- Full-year 2025 results, March 16, 2026
- European orphan medicinal product designation, July 28, 2026
- Prospectus supplement, February 2026 offering
- Definitive proxy statement, April 16, 2026
- Schedule 13D/A from Lantheus, September 23, 2026
- ClinicalTrials.gov, VMT-α-NET (NCT05636618)
- ClinicalTrials.gov, VMT01 (NCT05655312)
- ClinicalTrials.gov, PSV359 (NCT06710756)
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $CATX or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.
Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data, and companies that spend ahead of revenue raise equity at whatever price the market will bear. This company held approximately $202 million of cash, cash equivalents and short-term investments at September 30, 2026 against a $32.4 million quarterly net loss, has no approved product and approximately $54.5 million of contracted construction commitments, and had 13,672,484 options and 338,715 warrants outstanding at that date against 120,758,815 shares at November 4, 2026. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
